<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Bicara Therapeutics Inc. Common Stock — News on 6ix</title>
    <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock</link>
    <description>Latest news and press releases for Bicara Therapeutics Inc. Common Stock on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/bicara-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354b6c78dffbe2df0e516e.webp</url>
      <title>Bicara Therapeutics Inc. Common Stock</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock</link>
    </image>
    <item>
      <title>Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
      <description>Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027</description>
    </item>
    <item>
      <title>Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-updates-on-march-30-2026-at-830-am-et</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Wed, 04 Mar 2026 13:30:00 GMT</pubDate>
      <description>BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on March 2, 2026 to one new employee under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employee received a non-qualified stock option to purchase 115,000 shares of Bicara’s common stock, par value $0.0001</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-closing-of-oversubscribed-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-closing-of-oversubscribed-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares</guid>
      <pubDate>Thu, 26 Feb 2026 21:01:00 GMT</pubDate>
      <description>BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise price of $0.0001 per share. The shares of common stoc</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-pricing-of-dollar150-million-public-offering-of-common-stock-and-pre-funded-warrants</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-pricing-of-dollar150-million-public-offering-of-common-stock-and-pre-funded-warrants</guid>
      <pubDate>Wed, 25 Feb 2026 04:13:00 GMT</pubDate>
      <description>BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of an underwritten public offering of 7,175,000 shares of its common stock at a public offering price of $16.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of common stock at</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Proposed Public Offering of Common Stock</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-proposed-public-offering-of-common-stock</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-proposed-public-offering-of-common-stock</guid>
      <pubDate>Tue, 24 Feb 2026 21:01:00 GMT</pubDate>
      <description>BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Bicara intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock offered in the public offering, at the</description>
    </item>
    <item>
      <title>Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/ficerafusp-alfa-2000mg-q2w-demonstrates-deep-durable-responses-in-1l-rm-hpv-negative-hnscc-and-supports-development-of-less-frequent-dosing-regimen</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/ficerafusp-alfa-2000mg-q2w-demonstrates-deep-durable-responses-in-1l-rm-hpv-negative-hnscc-and-supports-development-of-less-frequent-dosing-regimen</guid>
      <pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
      <description>Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-inducement-grants-133000138</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-inducement-grants-133000138</guid>
      <pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
      <description>BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on February 2, 2026 to two new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 158,900 shares of Bicara’s common stock</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides-2026-corporate</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides-2026-corporate</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to</description>
    </item>
    <item>
      <title>Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-present-jp-morgan-2026-annual-healthcare-conference-monday</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-present-jp-morgan-2026-annual-healthcare-conference-monday</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing</description>
    </item>
    <item>
      <title>Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-preliminary-phase-1b-expansion-cohort-data-evaluating-750mg</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-preliminary-phase-1b-expansion-cohort-data-evaluating-750mg</guid>
      <pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
      <description>Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose,</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-publication-abstract-preliminary-phase-1b-expansion</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-publication-abstract-preliminary-phase-1b-expansion</guid>
      <pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
      <description>Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data</description>
    </item>
    <item>
      <title>Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-ficerafusp-alfa-113000241</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-ficerafusp-alfa-113000241</guid>
      <pubDate>Mon, 13 Oct 2025 11:30:00 GMT</pubDate>
      <description>Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCCBOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination</description>
    </item>
    <item>
      <title>Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC </title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-ficerafusp-alfa-granted-breakthrough-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-announces-ficerafusp-alfa-granted-breakthrough-therapy</guid>
      <pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
      <description>Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC BOSTON, Oct. 13, 2025</description>
    </item>
    <item>
      <title>Bicara Therapeutics to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-participate-upcoming-investor-conferences-2025-08-27</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-participate-upcoming-investor-conferences-2025-08-27</guid>
      <pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
      <description>BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing</description>
    </item>
    <item>
      <title>Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-reports-second-quarter-2025-financial-results-and-provides</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-reports-second-quarter-2025-financial-results-and-provides</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from</description>
    </item>
    <item>
      <title>Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/relay-therapeutics-appoints-claire-mazumdar-phd-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/relay-therapeutics-appoints-claire-mazumdar-phd-to-board-of-directors</guid>
      <pubDate>Wed, 11 Jun 2025 20:05:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board of Directors, effective June 9, 2025. “It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-sta</description>
    </item>
    <item>
      <title>Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-present-goldman-sachs-46th-annual-global-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-present-goldman-sachs-46th-annual-global-healthcare-conference</guid>
      <pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
      <description>BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing</description>
    </item>
    <item>
      <title>Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025</title>
      <link>https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-demonstrates-deep-and-durable-responses-ficerafusp-alfa-plus</link>
      <guid isPermaLink="true">https://6ix.com/company/bicara-therapeutics-inc-common-stock/news/bicara-therapeutics-demonstrates-deep-and-durable-responses-ficerafusp-alfa-plus</guid>
      <pubDate>Sun, 01 Jun 2025 04:00:00 GMT</pubDate>
      <description>Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median</description>
    </item>
  </channel>
</rss>